iA Global Asset Management Inc. Invests $1.32 Million in CG Oncology, Inc. (NASDAQ:CGON)

iA Global Asset Management Inc. bought a new stake in CG Oncology, Inc. (NASDAQ:CGON - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 45,890 shares of the company's stock, valued at approximately $1,316,000. iA Global Asset Management Inc. owned approximately 0.06% of CG Oncology at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. purchased a new position in CG Oncology in the 4th quarter valued at approximately $68,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of CG Oncology during the 3rd quarter worth $241,000. Arizona State Retirement System acquired a new position in shares of CG Oncology during the 4th quarter worth $340,000. Teacher Retirement System of Texas purchased a new stake in shares of CG Oncology in the 4th quarter worth about $342,000. Finally, Handelsbanken Fonder AB acquired a new stake in CG Oncology in the 4th quarter valued at about $381,000. 26.56% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at CG Oncology

In other CG Oncology news, Director Leonard E. Post sold 1,000 shares of CG Oncology stock in a transaction on Monday, January 13th. The shares were sold at an average price of $29.66, for a total value of $29,660.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Remove Ads

Analyst Upgrades and Downgrades

Several analysts have issued reports on CGON shares. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $66.00 price target on shares of CG Oncology in a report on Friday, December 6th. Morgan Stanley reiterated an "overweight" rating and set a $55.00 target price on shares of CG Oncology in a report on Friday, March 7th. TD Cowen started coverage on CG Oncology in a report on Tuesday, January 7th. They issued a "buy" rating for the company. Finally, HC Wainwright reaffirmed a "buy" rating and set a $75.00 price objective on shares of CG Oncology in a research note on Tuesday. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Buy" and an average target price of $63.88.

CG Oncology Stock Performance

CG Oncology stock traded down $1.00 during trading on Wednesday, hitting $26.54. The company's stock had a trading volume of 794,127 shares, compared to its average volume of 633,474. The stock's fifty day moving average is $28.07 and its 200 day moving average is $32.01. CG Oncology, Inc. has a 1-year low of $23.91 and a 1-year high of $46.99.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.